Study of IBI318 in Participants With Advanced Malignancies

0.3 mg intravenous infusion, C1D1 and afterwards Q2W

1 mg intravenous infusion, C1D1 and afterwards Q2W

3 mg intravenous infusion, C1D1 and afterwards Q2W

10 mg intravenous infusion, C1D1 and afterwards Q2W

30 mg intravenous infusion, C1D1 and afterwards Q2W

100 mg intravenous infusion, C1D1 and afterwards Q2W

300 mg intravenous infusion, C1D1 and afterwards Q2W

600 mg intravenous infusion, C1D1 and afterwards Q2W

Intravenous infusion, C1D1 and afterwards Q3W

Intravenous infusion, C1D1 and afterwards Q3W

Intravenous infusion Q3W